开发更好的治疗方案，能为大多数脑转移瘤 (BM) 患者提供帮助，十分必要。同样重要的是避免那些不能对特定患者有益的治疗方法。总的来说，已有的针对 BM 患者的治疗方案可以在分子层面和治疗效果上有所提升。通过对现今提供的全脑放疗的益处提出质疑，以及缺乏检测放射治疗耐受性的生物标志物，我们确定了 S100A9 和高级糖基化终末产物受体 (RAGE) 作为液体活检生物标志物和潜在放射敏感剂靶点。它们两个都正在临床测试中，是首个面向 BM 的个体化放疗全面分子策略的一部分。Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.

Developing better treatments that work for the majority of patients with brain metastasis (BM) is highly necessary. Complementarily, avoiding those therapeutic procedures that will not benefit a specific patient is also very relevant. In general, existing therapies for patients with BM could be improved in terms of molecular stratification and therapeutic efficacy. By questioning the benefit of whole brain radiotherapy as provided nowadays and the lack of biomarkers detecting radioresistance, we identified S100A9 and receptor for advanced glycation end-products (RAGE) as a liquid biopsy biomarker and a potential target for a radiosensitizer, respectively. Both of them are being clinically tested as part of the first comprehensive molecular strategy to personalized radiotherapy in BM.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.